Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Iovance Biotherapeutics (IOVA) is drawing attention ahead of its second quarter 2026 earnings report and corporate update scheduled for August 6, 2026, which will be presented alongside its first FDA-approved T cell therapy for solid tumors.

See our latest analysis for Iovance Biotherapeutics.

The latest pullback in Iovance Biotherapeutics, with a 1-day share price return down 13.22% and 7-day share price return down 18.44% to US$4.07, sits against a stronger backdrop that includes a 30-day share price return of 2.52%, 90-day share price return of 19.71%, and year to date share price return of 61.51%. The 1-year total shareholder return of 51.87% contrasts with weaker 3-year and 5-year total shareholder returns, suggesting short term momentum has picked up as investors weigh the first T cell therapy launch and the upcoming earnings report.

If you are looking beyond Iovance Biotherapeutics in cancer and immunotherapy, this could be a good moment to scan for other healthcare AI opportunities using the 41 healthcare AI stocks

Iovance Biotherapeutics now trades at US$4.07 while analyst targets and intrinsic value estimates sit much higher. The key issue is how much of that gap reflects caution on risks versus how much represents a clear valuation opportunity.

The most followed narrative on Iovance Biotherapeutics sets a fair value of $18.00 per share compared with the last close at $4.07. That gap frames a very bullish story that goes well beyond the upcoming earnings date.

Today, the market capitalization is only around $2 billion, despite Iovance already having an FDA-approved product and guidance for hundreds of millions of dollars in revenue this year.

If management executes as planned, I don't think the company should trade like an early-stage biotech anymore. Companies with approved oncology products and visible growth often trade at 4 to 6 times forward sales.

Want to see how this narrative gets from a commercial reset to that higher fair value for Iovance Biotherapeutics? The core assumptions sit in revenue growth, future margins and the valuation multiple placed on a maturing oncology franchise. Curious which of those levers does the heavy lifting in the model and how aggressive they really are? The full narrative breaks that down line by line.

Result: Fair Value of $18.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Iovance Biotherapeutics still faces meaningful risks if Amtagvi uptake falls short of expectations or if future TIL trial results disappoint and delay broader use.

Find out about the key risks to this Iovance Biotherapeutics narrative.

With sentiment on Iovance Biotherapeutics split between clear risks and meaningful potential rewards, it may be useful to act promptly and examine the data yourself through the 3 key rewards and 2 important warning signs.

Do not stop with just one story. Broaden your watchlist and give yourself more options by checking other stocks that fit clear, data driven criteria.

Target potential turnaround opportunities by scanning 21 elite penny stocks with strong financials that already show stronger underlying financial profiles than typical low priced stocks.

Focus on quality at a sensible price by reviewing the 55 high quality undervalued stocks that combine solid fundamentals with valuations that may not fully reflect them yet.

Prioritise resilience and support more stable investing by checking the 81 resilient stocks with low risk scores that score well on balance sheet strength and risk indicators.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IOVA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]